Results 111 to 120 of about 1,744 (184)

GRAM+ Acute Bacterial Skin And Skin Structure Infections (ABSSSI): Recent Trends In United States Hospital Admissions [PDF]

Value in Health, 2014
Khachatryan, A, Stephens, J.M., Johnson, K.E., Patel, D.A., Patel, A., Kaye, K.S.   +5 more
openaire   +2 more sources

Ceftaroline Fosamil (CPT) vs. Vancomycin (VAN) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) [PDF]

Open Forum Infectious Diseases, 2017
Trang D Trinh, Evan J Zasowski, Kimberly Claeys, Abdalhamid M Lagnf, Dino Delaportas, Sandy Estrada, Susan L Davis, Kenneth Klinker, Vanthida Huang, Keith S Kaye, Nicole Bonine, Patrick Gillard, Michael J Rybak   +12 more
openaire   +1 more source

Usefulness of dalbavancin in early discharge and non-hospitalization. It’s time to throw your heart over the obstacle?

Global & Regional Health Technology Assessment
Introduction: Dalbavancin is a semisynthetic lipoglycopeptide long-acting antibiotic approved for the treatment of acute bacterial skin and skin structure infections (ABSSSIs).
Massimo Crapis, Sergio Venturini, Astrid Callegari, Giovanni Del Fabro, Igor Bramuzzo, Laura De Santi, Elisa Pontoni, Maurizio Tonizzo, Barbara Basso   +8 more
doaj   +1 more source

Analisi preliminare sull’impatto clinico-organizzativo della gestione delle ABSSSI: focus sui criteri di dimissione precoce

, 2019
INTRODUZIONE: Le Acute Bacterial Skin and Skin Structure Infections (ABSSSI) sono patologie eterogenee, solitamente di modesta gravità. Possono tuttavia manifestarsi con quadri clinici più severi, pertanto la gestione può risultare complessa, con conseguenti costi sociali ed economici rilevanti.
G. Stella, C. Cassol, S. Modica, D. Marri, L. Migliorini, B. Rossetti, G. Zanelli, F. Montagnani   +7 more
openaire   +1 more source

Real-life experience with IV dalbavancin in Canada; results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry

Journal of Global Antimicrobial Resistance
: Objectives: We report the use of IV dalbavancin in Canadian patients using data captured by the national CLEAR registry. Methods: The CLEAR registry uses the web-based data management program, REDCap™ (online survey https://rcsurvey.radyfhs.umanitoba ...
George Zhanel, Michael Silverman, Janhavi Malhotra, Melanie Baxter, Reza Rahimi, Neal Irfan, Gabriel Girouard, Rita Dhami, Melissa Kucey, Vida Stankus, Kristin Schmidt, Sébastien Poulin, William Connors, Carlo Tascini, Andrew Walkty, James Karlowsky   +15 more
doaj   +1 more source

Impact of first-line dalbavancin for cellulitis on hospital admissions and costs: A case series

Journal of Global Antimicrobial Resistance
Background: Many patients with cellulitis are treated with oral antibiotics as outpatients, but some require hospital admission for intravenous antibiotics.
Kailey Ben-Sassi, Suhail Sarwar
doaj   +1 more source

In vitro activity of omadacycline against bacterial isolates from bone/joint infections and rare pathogens in the SENTRY antimicrobial surveillance program (2015–2023)

Journal of Global Antimicrobial Resistance
Objectives: Omadacycline is an aminomethylcycline (tetracycline class) antibacterial approved by the United States Food and Drug Administration (2018) for treatment of adults with acute bacterial skin and skin structure infection (ABSSSI) and community ...
Michael D. Huband, Paul R. Rhomberg, Kelley A. Fedler, Christopher Blankers, Diane Anastasiou, Alisa W. Serio, Mariana Castanheira   +6 more
doaj   +1 more source

Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects [PDF]

, 2015
Mark Yen, Michael W. Dunne, Patrick J. Scoble, Robert C. Owens, Sailaja Puttagunta   +4 more
core   +1 more source

Acute Bacterial Skin And Skin Structure Infection (Absssi): Development Of A New Patient Reported Outcome (Pro) [PDF]

Value in Health, 2014
Powers, J.H., Portalupi, S., Devine, J., Saretsky, T.L., Hoffmann, S., Crawley, J., Lorens, L., Cimms, T.A., Howard, K.   +8 more
openaire   +2 more sources

All-Cause Readmission Following Treatment With Linezolid for MRSA-ABSSSI: A Propensity Score Analysis

Open Forum Infectious Diseases, 2015
Emily T. Martin, Richard Evans, Matthew Compton, Jason Pogue, Paul Lephart, Michael J. Rybak, Keith Kaye, Susan L. Davis   +7 more
openaire   +1 more source